Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Zachariah DeFilipp

Showing results (81-90 of 141) with videos related to

Pageof 15
Sort By:
Transplantation and Cellular Therapy|October 16, 2023
Severity of Chronic Graft-versus-Host Disease and Late Effects Following Allogeneic Hematopoietic Cell Transplantation for Adults with Hematologic MalignancyCatherine J Lee, Tao Wang, Karen Chen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 4, 2023
Multicenter Phase I Trial of Ivosidenib as Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplantation for IDH1-Mutated Acute Myeloid LeukemiaAmir T Fathi, Haesook T Kim, Robert J Soiffer, et al.
Cancer|January 25, 2017
Cytogenetic risk determines outcomes after allogeneic transplantation in older patients with acute myeloid leukemia in their second complete remission: A Center for International Blood and Marrow Transplant Research cohort analysisFotios V Michelis, Vikas Gupta, Mei-Jie Zhang, et al.
Blood Advances|April 19, 2024
The MAGIC algorithm probability predicts treatment response and long-term outcomes to second-line therapy for acute GVHDZachariah DeFilipp, Haesook T Kim, Nikolaos Spyrou, et al.
Blood Advances|March 12, 2024
Third-party fecal microbiota transplantation for high-risk treatment-naïve acute GVHD of the lower GI tractZachariah DeFilipp, Ashish V Damania, Haesook T Kim, et al.
Blood|February 15, 2022
Safety and efficacy of tisagenlecleucel in primary CNS lymphoma: a phase 1/2 clinical trialMatthew J Frigault, Jorg Dietrich, Kathleen Gallagher, et al.
Blood Advances|February 10, 2025
Single-cell dynamics of breakthrough toxicities after anakinra prophylaxis for axicabtagene ciloleucel in lymphomaMatthew J Frigault, Ning Yao, Trisha R Berger, et al.
Blood Advances|September 8, 2021
Autologous and allogeneic hematopoietic cell transplantation for diffuse large B-cell lymphoma-type Richter syndromeAlex F Herrera, Kwang Woo Ahn, Carlos Litovich, et al.
Transplantation and Cellular Therapy|March 28, 2024
A Validated Risk Stratification That Incorporates MAGIC Biomarkers Predicts Long-Term Outcomes in Pediatric Patients with Acute GVHDMuna Qayed, Urvi Kapoor, Scott Gillespie, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|November 25, 2015
Significant Improvements in the Practice Patterns of Adult Related Donor Care in US Transplantation CentersChloe Anthias, Bronwen E Shaw, Deidre M Kiefer, et al.
Pageof 15

Showing results (81-90 of 141) with videos related to

Sort By:
Pageof 15
Transplantation and Cellular Therapy|October 16, 2023
Severity of Chronic Graft-versus-Host Disease and Late Effects Following Allogeneic Hematopoietic Cell Transplantation for Adults with Hematologic MalignancyCatherine J Lee, Tao Wang, Karen Chen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 4, 2023
Multicenter Phase I Trial of Ivosidenib as Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplantation for IDH1-Mutated Acute Myeloid LeukemiaAmir T Fathi, Haesook T Kim, Robert J Soiffer, et al.
Cancer|January 25, 2017
Cytogenetic risk determines outcomes after allogeneic transplantation in older patients with acute myeloid leukemia in their second complete remission: A Center for International Blood and Marrow Transplant Research cohort analysisFotios V Michelis, Vikas Gupta, Mei-Jie Zhang, et al.
Blood Advances|April 19, 2024
The MAGIC algorithm probability predicts treatment response and long-term outcomes to second-line therapy for acute GVHDZachariah DeFilipp, Haesook T Kim, Nikolaos Spyrou, et al.
Blood Advances|March 12, 2024
Third-party fecal microbiota transplantation for high-risk treatment-naïve acute GVHD of the lower GI tractZachariah DeFilipp, Ashish V Damania, Haesook T Kim, et al.
Blood|February 15, 2022
Safety and efficacy of tisagenlecleucel in primary CNS lymphoma: a phase 1/2 clinical trialMatthew J Frigault, Jorg Dietrich, Kathleen Gallagher, et al.
Blood Advances|February 10, 2025
Single-cell dynamics of breakthrough toxicities after anakinra prophylaxis for axicabtagene ciloleucel in lymphomaMatthew J Frigault, Ning Yao, Trisha R Berger, et al.
Blood Advances|September 8, 2021
Autologous and allogeneic hematopoietic cell transplantation for diffuse large B-cell lymphoma-type Richter syndromeAlex F Herrera, Kwang Woo Ahn, Carlos Litovich, et al.
Transplantation and Cellular Therapy|March 28, 2024
A Validated Risk Stratification That Incorporates MAGIC Biomarkers Predicts Long-Term Outcomes in Pediatric Patients with Acute GVHDMuna Qayed, Urvi Kapoor, Scott Gillespie, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|November 25, 2015
Significant Improvements in the Practice Patterns of Adult Related Donor Care in US Transplantation CentersChloe Anthias, Bronwen E Shaw, Deidre M Kiefer, et al.
Pageof 15